The Future of Monoclonal Antibodies Therapeutics: Innovation In Antibody Engineering, Key Growth Strategies And Forecasts To 2011 - Biologics Market Research

The Future of Monoclonal Antibodies Therapeutics: Innovation In Antibody Engineering, Key Growth Strategies And Forecasts To 2011
Business Insights
July 1, 2006
180 Pages
Pub ID: RET1326939
US $2,875.00 Online Download
US $13,350.00 Global Site License
Abstract
The monoclonal antibody (mAb) market has grown rapidly in recent years, reaching sales of $14bn in 2005, an increase of 36.5% from 2004 sales of $10.3bn. K?hler and Milstein developed the hybridoma method of murine antibody production in 1975, which allowed the production of the first mAb to market; Johnson & Johnson?s Orthoclone OKT3 (muromonab) in 1986. The mAb market is highly innovative and a key trend has been the move from murine to humanized and fully human antibodies. As technology has progressed these humanized mAbs have prevented immune responses (HAMA), thus having a larger market potential. The traditional therapy areas in the mAb market are oncology and autoimmune and inflammatory disorders (AIID), however this is forecast to change with the emergence of other therapy areas including infectious disease and ophthalmology. The clear leader in the mAb market is Genentech with 5 marketed drugs, with sales totaling $4,116.4m in 2005. A key theme of this report is the high level of innovation, as demonstrated by advancements in antibody engineering with the introduction of chimeric, humanized and fully human mAbs. Other innovation in antibody technology include advancements in non-invasive drug delivery technology, which is predicted to lead to a huge boost in sales in the long-term once drugs that utilize this technology come to market.
Key findings of the report:
The antibody market is set to more than double in value over the next 5 years to $29.7bn, continuing the rapid growth witnessed in the past 2 years.
During the next 5 years antibodies for oncology and arthritis, immune and inflammatory disorders (AIID) are forecast to continue to lead the market, with sales of $14bn and $11bn, respectively in 2011.
With the predicted launch of 2 pipeline antibodies in the next 5 years, the infectious disease area is set to grow in importance. Antibodies are also being developed in respiratory, cardiovascular and ophthalmology indications.
Analysis of early and late stage pipelines show development focus is shifting away from murine and chimeric mAbs to humanized and fully human antibodies. Abbott/CAT?s Humira, launched in the US in 2003, was the first fully human antibody on the market.
Genentech and Roche held a combined 48.7% share of the antibodies market in 2005, primarily due to the success of their collaborative oncology drugs, Rituxan, Herceptin and Avastin.
Key questions answered in this report:
What were the key events in the global mAb market in 2005-06?
What are the opportunities and threats to key players in this market?
Which companies are innovators in the mAb market and who have they formed collaborations with?
What is the sales forecast in each therapy area of the mAb market over the period 2005-11?
What are current and future leading brands in the global mAb market?
What strategies are the leading companies implementing to maximize sales and boost market share?
Which new product launches are forecast to gain blockbuster status?
Additional Information
Top five reasons to order your copy today:
Assess the sales growth potential of antibodies in each therapeutic market through the 5-year forecasts in oncology, AIID, infectious diseases, respiratory, cardiovascular and ophthalmology indications.
Evaluate the future of the monoclonal antibodies market in 2011 and assess your potential competitive position, through the report?s extensive pipeline insight and profiles of upcoming launches.
Implement strategies to overcome the key current and future challenges in the antibodies market, including issues of pricing and reimbursement, competition from targeted small molecule drugs and the threat of biosimilars.
Anticipate future trends in the market by using the report?s in-depth analysis of innovation in drug discovery platforms, antibody engineering and non-invasive drug delivery.
Identify the critical success factors for your company to succeed in the antibody market, through examination of successful growth strategies used by the leading antibody drug developers and technology innovators.